Lithium suppression of tau induces brain iron accumulation and neurodegeneration

P Lei1,2, S Ayton2, AT Appukuttan2, S Moon2, JA Duce2,3, I Volitakis2, R Cherny2, SJ Wood4,5, M Greenough2, G Berger6,7, C Pantelis2,4,8, P McGorry6, A Yung9, DI Finkelstein2 and AI Bush2

INTRODUCTION

Lithium is a first-line therapy for bipolar affective disorder. However, various adverse effects, including a Parkinson-like hand tremor, often limit its use. The understanding of the neurobiological basis of these side effects is still very limited. Nigral iron elevation is also a feature of Parkinsonian degeneration that may be related to soluble tau reduction. We found that magnetic resonance imaging T2 relaxation time changes in subjects commenced on lithium therapy were consistent with iron elevation. In mice, lithium treatment lowers brain tau levels and increases nigral and cortical iron elevation that is closely associated with neurodegeneration, cognitive loss and parkinsonian features. In neuronal cultures lithium attenuates iron efflux by lowering tau protein that traffics amyloid precursor protein to facilitate iron efflux. Thus, tau- and amyloid protein precursor-knockout mice were protected against lithium-induced iron elevation and neurotoxicity. These findings challenge the appropriateness of lithium as a potential treatment for disorders where iron levels are elevated (for example, Alzheimer’s disease), and may explain lithium-associated motor symptoms in susceptible patients.

Molecular Psychiatry advance online publication, 12 July 2016; doi:10.1038/mp.2016.96
and mRNA levels in cultured cortical neurons. Supporting this concept, long-term (5 months) lithium treatment of PTP T44 tau transgenic mice resolved tau aggregates by promoting ubiquitination and degradation of tau, rather than altering GSK-3 activity.

We, and others, have reported concerns that lowering levels of brain tau could induce age-dependent neurodegeneration. In tauopathies (such as AD and PD), insoluble tau aggregates are accompanied by a fall in soluble tau levels in affected tissue. We have argued that this will lead to a loss of tau function that could cause neurodegeneration, as tau functions to lower neuronal iron levels by promoting the presentation of the amyloid protein precursor (APP) to the neuronal surface, where it promotes the efflux of iron.

Without soluble tau, neurons accumulate iron to toxic levels, and hence tau-knocked-out mice develop a parkinsonism with impaired-cognition phenotype that is rescued by iron chelation. Iron accumulation in the substantia nigra (SN) is a robust feature of PD, and is a sufficient cause for parkinsonism (reviewed in Ayton and Lei). There has been one case report of such SN iron elevation with extra-pyramidal signs following long-term lithium treatment. We hypothesized that as lithium lowers neuronal tau, lithium could engender SN iron accumulation and induce parkinsonian neurodegeneration, explaining a cryptogenic aspect of its adverse effect profile.

MATERIALS AND METHODS

Reagents

Reagents were purchased from Sigma-Aldrich (Castle Hill, NSW, Australia), unless specified.

The lithium clinical imaging study

The lithium clinical imaging study has been previously described. The pilot study was conducted as an open-label, non-randomized, controlled single-center study. Participants were consecutively referred to the Personal Assessment and Crisis Evaluation (PACE) Clinic, a specialist clinic for young people at ultrahigh risk (UHR) for psychosis. PACE is a subprogram of ORYGEN Youth Health, a specialist service for young people with emerging mental disorders. Inclusion criteria for PACE were: (1) age between 14 and 30 inclusive years, (2) resident of the Melbourne metropolitan area or the ability to travel to the PACE clinic at least once a week and (3) meeting PACE UHR criteria. UHR criteria were determined using the Comprehensive Assessment of the At Risk Mental State (CAARMS). Rationale and validity for these criteria have been fully described elsewhere. Exclusion criteria were: (1) medical or neurological conditions that may diminish functioning or that may account for some of the symptoms leading to the initial referral, for example, epilepsy; (2) clinically relevant biochemical or hematological abnormalities; (3) serious coexisting illnesses such as liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological or metabolic disturbances (including patients known to be HIV positive); (4) history of previous acute psychotic episodes either treated or untreated; (5) a current score of 5 or 6 on the CAARMS Mania item or a history of a previous manic episode; (6) any previous use of neuroleptic or mood-stabilizing medications; (7) history of severe drug allergy or hypersensitivity; (8) history of intellectual disability (IQ < 70); and (9) inability to understand or communicate in English. All UHR subjects received PACE treatment as usual throughout the course of the study including psychological and medical treatment. Use of antidepressants was allowed if UHR patients met criteria for major depression. UHR subjects in the low-dose lithium group took one slow-release 450 mg tablet of lithium carbonate each night for the entire study period (3 months), intended to achieve serum lithium levels of 0.3–0.5 μM, in addition to treatment as usual.

Baseline magnetic resonance imaging scans and clinical assessments were conducted before commencement of the low-dose lithium treatment, and within 2 weeks of admission to the study. Monitoring of psychopathology and tolerability measures occurred at monthly intervals, and follow-up scanning was conducted as close as possible to 3 months after baseline (median for the control group was 3 months, range 0.8–27 months; for the lithium group 3.8 months, range 1.6–5.9 months, with some subjects in both groups not completing the full treatment period). Extrapyramidal side effects were not systematically assessed. The local research and ethics committee approved the study protocol. All participants gave written informed consent. Additional written informed consent was obtained from parents or guardians for participants aged 14–18 years. Participants were made aware that they could withdraw from the study at any time and that withdrawal would not compromise access to any clinical services.

Brain imaging and SN T\textsubscript{2} relaxometry

All scans were performed on a 3T GE LX Horizon scanner (GE Healthcare, Milwaukee, WI, USA) at the Brain Research Institute (Melbourne, Victoria, Australia). Eight tilted, coronal T\textsubscript{2}-weighted images (perpendicular to the long axis of the hippocampus) were obtained over a range of echo times (29 to 231 ms; TR = 4 s, slice thickness = 6 mm with 1.5 mm gap, matrix 256 x 256, field of view 24 cm). Single exponentials were then fitted to the image data of corresponding voxels from these eight echoes using iBrain (Brain Research Institute). This created a series of T\textsubscript{2} maps, one for each coronal slice. The brightness of each individual voxel on this map represents its calculated T\textsubscript{2} relaxation time. The images were then analyzed in various regions of interest with reference to a standard neuroanatomical atlas by two raters who were blinded to treatment group, and quantified using ANALYZE 7.2 software (Mayo Clinic, Rochester, MN, USA), as previously described.

Primary neuron culture

Primary neurons were prepared as previously described. Briefly, cortices of wild-type and tau-knockout embryos (day 14) were dissected and dissociated in 0.025% (w/v) trypsin. The neurons were plated (Nunc, Mt Waverley, VIC, Australia) at a density of 600 000 cells per cm\textsuperscript{2} in plating medium (Dulbecco’s modified Eagle’s medium with 10% fetal calf serum, 5% house serum and 10 μg/ml gentamycin sulfate; Invitrogen, Mt Waverley, VIC, Australia). After 2 h of incubation, the neurons were changed to Neurobasal supplemented medium (with B27, 500 μM glutamine and 10 μg/ml gentamycin sulfate). Experiments were performed 7 days later. Confluent cells were incubated in Neurobasal medium solution before treatment with various concentrations of lithium chloride for 18 h with or without radioactive \textsuperscript{59}Fe or \textsuperscript{65}Zn, or various compounds (L690,330; 6-bromindirubin-3-oxime (BIO)) at concentrations indicated. The cells were then harvested, with half the batch lysed using lysis buffer (1% Triton X-100, 50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, pH 7.4, together with 1.5% proteinase inhibitor and 1:100 kinase inhibitors l and II), and the other half retained for metal analysis (see below), or assayed for radioactive tracers by γ-counter.

\textsuperscript{59}Fe-loaded transferrin and \textsuperscript{65}Zn preparation

Purified human apo-transferrin (Tf) was loaded with \textsuperscript{59}Fe (Perkin Elmer, Glen Waverley, VIC, Australia) to form Tf(\textsuperscript{59}Fe)\textsubscript{2}, as previously described. Neurons were incubated with 1.0 × 10\textsuperscript{-10} M Tf(\textsuperscript{59}Fe)\textsubscript{2} in serum-free Neurobasal supplemented medium for periods indicated. At the conclusion of the treatments, neurons were washed thoroughly with phosphate-buffered saline (PBS) and harvested with trypsin. All media and cell lysates were measured by γ-counter (Wizard 3, Perkin Elmer) for counts per min. For iron efflux assay, cells were incubated at 37 °C and medium was removed at select time points. A comparable time-course control study was performed at 4 °C to account for nonspecific binding of \textsuperscript{59}Fe to the membrane surface.

The \textsuperscript{65}Zn experiments were adapted from a previous publication. Briefly, serum-free Neurobasal supplemented medium was mixed with 0.04 MBq \textsuperscript{65}Zn (Oak Ridge Laboratory, Oak Ridge, TN, USA) and unlabeled ZnCl\textsubscript{2} (20 μM). After 18 h of treatment, the reaction was stopped by washing cell monolayers three times with ice-cold nonlabeled Hanks’ balanced salt solution (with 2 μM l-histidine and 5 mM EDTA). The cells were then harvested and measured for \textsuperscript{65}Zn retention by γ-counter (1282 CompuGamma; LKB Wallac, Mt Waverley, VIC, Australia).

Mouse tissue preparation

All mice were housed in a conventional animal facility according to standard animal care protocols and fed standard laboratory chow (Meat Free Rat and Mouse Diet, Specialty Feeds, Glen Forrest, WA, Australia) and tap water ad libitum. All animal procedures were approved by the Florey Institute animal ethics committee (10-017) and were performed in

Molecular Psychiatry (2016), 1–11
© 2016 Macmillan Publishers Limited
Lithium treatment to mice
The 3-month-old male B6/C57J mice (used in Figure 2) as well as age-matched intact control mice (BL6/129sv) were gavaged with lithium chloride (3.6 mg kg⁻¹) per day, for 21 days. To control for effects of potential acute sedation, BL6/C57J mice were habituated to the pole and allowed 1 h to acclimatize to its surroundings. Parameters of movements were calculated from the interception of beams to provide an XY coordinate. For Y-maze test, a Y-shaped gray-painted timber with arms 25.4 cm deep by 40.6 cm high. The mouse was placed in the chamber for 1 h to allow acclimatization to its surroundings. All mice were subjected to a two-trial Y-maze test separated by a 1-h interp trial interval to assess spatial recognition memory, with all testing performed during the light phase of the circadian cycle. The three identical arms were randomly designated start arm, novel arm and other arm. Visual cues were placed on the walls of the maze. The first trial (training) was for 10 min, and the mice were allowed to explore only 2 arms (starting arm and other arm). For the second trial (retention), mice were placed back in the maze in the same starting arm, and allowed to explore for 5 min with free access to all 3 arms. Behaviors were recorded on video during a 5-min trial and the Ethovision video-tracking system (Noldus, Wageningen, The Netherlands) was used for analysis. Data are expressed as the percentage of frequency and duration for novel arm entries made during the 5-min second trial. All behavioral tests were performed by an investigator blinded to the experimental group.

Anatomical morphology from brain slice
The anatomical morphology was examined as previously described.

Briefly, caudate/putamen (CPU) and cerebellum sections from mice were sectioned using a Leica Cryostat (North Ryde, NSW, Australia) at 50 μm thickness and areas of interest were measured using Image-J (v1.49b, NIH, Bethesda, MD, USA), using landmarks (anterior commissure for CPU and floculus for cerebellum) to identify the depth of coronal sectioning.
concentrations were separated in 4–12% Bis-Tris gels with NuPAGE MES running buffer (Invitrogen), and transferred to nitrocellulose membranes by iBlot (Invitrogen). The membranes were blocked with milk (10% w/v) and probed with appropriate primary and secondary IgG-horseradish peroxidase-conjugated antibodies (Dako, North Sydney, NSW, Australia). Enhanced chemiluminescence detection system (GE Healthcare) with the Fuji LAS-3000 (Campbellfield, VIC, Australia) was used for visualization. Densitometric quantification of immunoreactive signals was performed by ImageJ (1.49b, NIH) and normalized to the relative amount of β-actin and expressed as a percentage of the mean of the control group. The first three primary antibodies were used in the current study: anti-β-actin (Sigma), anti-tau (Dako) and anti-pTau396 (Invitrogen).

Statistics
Statistical analysis was carried out in Prism 6 (GraphPad Software, La Jolla, CA, USA) and power calculations were performed using PASS 13 (trial version, NCSS Statistical Software, Kaysville, UT, USA) based on the variance of results in our previous publication10 and in pilot experiments. Equivalence of variance between experimental groups was confirmed using Levene’s test, when applicable. Normal distribution was assumed for all statistical analyses. All tests were two tailed, with the level of significance set at 0.05. Specific types of test used for each experiment are described in the figure legends.

RESULTS
Low-dose lithium treatment induces reversible T2* changes in the SN consistent with iron elevation
To determine whether lithium treatment has the potential to raise nigral iron levels, we analyzed this nucleus in scans from a To determine whether lithium treatment has the potential to raise nigral iron levels, we analyzed this nucleus in scans from a

To determine whether lithium treatment has the potential to raise nigral iron levels, we analyzed this nucleus in scans from a

The impact of low-dose lithium treatment on hippocampal tissue integrity in individuals at UHR for psychosis was assessed by T2 relaxometry in an open-labeled, nonrandomized, controlled, single-center pilot study. Participants were treated with lithium or as usual for 3 months, and repeated 3T magnetic resonance images were taken from participants before commencement of the study (scan one) and after drug withdrawal (scan two). Lithium treatment induced a decrease in hippocampal T2 relaxation time34 that could not only indicate an improvement in various neuropathologies (for example, edema), but also reflect an increase in tissue iron.61–65

As iron elevation in the SN could contribute to Parkinson-like side effects such as the commonly observed hand tremor, we revisited this study and measured T2 relaxation in this region, as well as other comparison regions in the same coronal planes (as marked in Supplementary Figure 1a, with reference to a standard neuroanatomical atlas). We found that the average T2 relaxation time in the SN of the lithium group at 3 months (scan two) was significantly reduced from baseline (scan one) (−5%, P = 0.007), and significantly lower than the control (treatment as usual) group at the same time point (−7%, P < 0.001; Figures 1a and b), consistent with iron accumulation or edema. The pattern of changes was similar in both hemispheres. Other regions analyzed, caudate and lenticular nucleus, showed no change in T2 relaxation time (P = 0.18 for caudate and P = 0.29 for lenticular nucleus; Supplementary Figure 1b) compared with the baseline scan. The lateral ventricular cross-sectional area was also unchanged from baseline (P = 0.17; Supplementary Figure 1b).

Iron accumulation and parkinsonism in a mouse model of lithium therapy
To test whether lithium-induced relaxometry changes could be due to brain iron accumulation, 3-month-old C57/Bl6J mice were orally administered lithium chloride at a low therapeutic dose40 (3.6 mg kg⁻¹ body weight per day) for 21 days. The dose was well tolerated and body weight was unaltered during the treatment period (P = 0.188; Figure 2a). Lithium levels were elevated in all tested tissues (P < 0.001 for cortex, SN, cerebellum and liver), with the greatest proportional elevation in cortex (+363%) and SN (+152%; Figure 2b). Iron levels were increased in cortex (+40%, P = 0.008) and SN (+19%, P = 0.039), but not cerebellum, liver or plasma (Figure 2c). The effect of lithium on biological metals was specific to iron, with copper and zinc unaltered in all tested tissues (Supplementary Figures 2a and b). Lithium levels significantly correlated with iron levels in SN (P = 0.007, R² = 0.62; Figure 2d) and cortex (P = 0.026, R² = 0.439; Supplementary Figure 3a) in lithium-treated mice, consistent with elevated lithium causing an elevation in iron. The correlation was seen neither in sham-treated SN (R² = 0.02; Figure 2d) nor cortex (R² = 0.03; Supplementary Figure 3a), nor observed in the cerebellum of lithium- (R² = 0.01) or sham-treated (R² = 0.05) animals, a region that did not accumulate iron with lithium treatment (Supplementary Figure 3b). Neither copper nor zinc correlated with lithium in these tissues (Supplementary Figures 3c and d).

We assessed the brains of lithium-treated mice to determine whether a drop in soluble tau could explain the iron elevation.43 As expected,36,38,39,66 the fraction of brain tau phosphorylated at Ser396 was suppressed by lithium treatment (cortex: −40%, P = 0.034; SN: −43%, P = 0.039; Supplementary Figure 4). We also discovered that lithium administration lowered PBS-soluble total tau levels in cortex and SN (cortex: −31%, P = 0.032; SN: −42%, P < 0.001; Figure 2e).

As tau loss causes iron-mediated neurodegeneration with parkinsonism,43–45 we investigated whether lithium treatment impaired motor function in these mice. Lithium-treated mice compared with sham-treated mice exhibited a significant increase in time to turn (P = 0.008; Figure 2f) and to finish (P = 0.041; Supplementary Figure 5a) on the Pole test, and significantly impaired performance on the accelerated Rotarod test as evidenced by reduced latency to fall (P = 0.004; Figure 2g) and lower average speed to fall (at speed 6, P < 0.001; at speed 7, P = 0.015; Supplementary Figure 5b). Rotarod impairment has previously been noted in 10-month-old mice treated for 4 weeks with lithium, but the cause was not ascertained.39 Lithium-treated mice also exhibited reduced locomotion distance (P = 0.022; Supplementary Figure 5c), reduced velocity (P = 0.023; Supplementary Figure 5d) and reduced average distance per movement (P = 0.018; Supplementary Figure 5e), without alterations in movement duration or time spent in the corners (data not shown) in the open field test.

Control studies were performed to ascertain whether short-term sedation67 could have contributed to the motor impairment induced by lithium. Diazepam, a sedative with well-characterized
effects on motor behaviors was compared with lithium within 2 h after dose for acute motor behavioral effects. Single-dose lithium or diazepam did not impair mouse Rotarod performance at this interval (Supplementary Figure 6a). Diazepam, but not lithium, induced a sudden drop in spontaneous locomotion 20 min after dosing in the open field test ($P = 0.006$; Supplementary Figure 6b). These data indicate that motor impairments induced by lithium were not due to sedation.

To determine whether the motor deficits induced by lithium could be because of Parkinson-like neuropathology, the TH-immunoreactive (dopaminergic) neurons within the SN were stereologically counted. The dopaminergic neurons were significantly decreased in mice treated with lithium for 21 days ($−30\%$, $P < 0.001$; Figures 2h and i), but TH-negative, Neutral Red-positive neurons were unaltered (Supplementary Figure 7a). Accompanying this loss, dopamine ($−40\%$, $P = 0.023$; Figure 2j) and...
3,4-dihydroxyphenylacetic acid (DOPAC; ~37%, P = 0.024; Supplementary Figure 7b) levels in the striatum were also decreased in lithium-treated mice. Excess dopamine induces hyperactivity, a characteristic of mania,

72 and is attenuated by lithium treatment.

73 Lithium decreases dopaminergic release

74 and suppresses levels of dopamine and its metabolites in the striatal projection field and nucleus accumbens.

75 Our findings indicate that suppression of the SN–striatal dopaminergic pathway may contribute to the motor deficits induced by lithium as well as, potentially, to its long-term antimanic and antipsychosis properties.

3. Lithium elevates brain iron via tau

P Lei et al

Figure 3. Lithium (Li)-induced iron elevation is caused by tau reduction in primary neuronal culture. (a) Li treatment to neurons for 18 h induced dose-dependent 59Fe retention (P = 0.005 for 5 mM Li, P < 0.001 for 10 mM Li, one-way analysis of variance (ANOVA), n = 4 per treatment). (b) Li treatment of neurons for 18 h induced specific iron elevation (P < 0.001, two-tailed t-test, n = 6 per treatment), without altering copper or zinc. (c) Li treatment (10 mM) inhibited iron export (P < 0.001, nonlinear regression with extra sum-of-squares F test, n = 6 per group). (d) Li treatment reduced neuronal tau levels (representative blots shown beneath) at 5 mM (P = 0.007) and 10 mM (P = 0.034, one-way ANOVA) after 18 h; n = 4 per group. (e) Tau-knockout neurons retained more 59Fe iron (P = 0.032) (18 h) but, in contrast to wild-type neurons, were resistant to Li-induced iron accumulation (P = 0.038, two-way ANOVA); n = 4 per group. Each experiment was independently repeated three times. Mean ± s.e.m. are shown. *P < 0.05, **P < 0.01, ***P < 0.001.

Figure 4. Lithium (Li)-induced parkinsonism is mediated by tau and amyloid protein precursor (APP). (a) Daily mean weights of the mouse cohorts revealed no significant impact of lithium treatment within each genotype group during the course of study. APP-knockout mice were lighter, as reported previously.

78 (b) Li treatment significantly elevated plasma lithium levels of 3-month-old wild-type (P < 0.001, two-way analysis of variance (ANOVA) with post hoc Dunnett’s test), tau-knockout (P < 0.001) and APP-knockout (P = 0.007) mice. These concentrations are well below the usual therapeutic range of clinical lithium therapy. (c) Elevated iron levels were observed in the cortex (P = 0.031, two-way ANOVA with post hoc Dunnett’s test) and substantia nigra (SN; P = 0.041) of Li-treated wild-type mice, but loss of tau or APP abolished the elevation. (e, f) Li treatment induced tau reduction in cortex and SN of both wild-type (P = 0.041 for cortex, P < 0.001 for SN, two-tailed t-test) and APP-knockout mice (f, P = 0.006 for cortex, P = 0.041 for SN, two-tailed t-test). (g, h) Li-treated wild-type mice required longer time to turn in the Pole test (g, P = 0.020, two-way ANOVA with post hoc Dunnett’s test) and showed significantly reduced average distance per movement in the open field test (h, P < 0.001), but loss of tau or APP protected against Li-induced motor impairment. (i) Li treatment caused SN dopaminergic neuron loss (P < 0.001, two-way ANOVA with post hoc Dunnett’s test), but did not cause similar neuronal loss in tau-knockout or APP-knockout mice. (j) Li treatment impaired cognitive function of wild-type mice, evidenced by significantly reduced novel arm duration in the Y-maze test (P = 0.022, two-tailed t-test). Such impairment was not evident in tau-knockout and APP-knockout mice. (k) Representative coronal section of cerebrum of wild-type mice treated with sham (left) or Li (right). Arrow indicates the landmark used to identify the section. Lines indicate the area quantified. (l) Significant enlargement of lateral ventricular (LV) was found in Li-treated wild-type mice (P = 0.023, two-way ANOVA with post hoc Dunnett’s test), but not in Li-treated tau-knockout or APP-knockout mice; n = 9–11 per treatment group. Mean ± s.e.m. are shown. *P < 0.05, **P < 0.01, ***P < 0.001.
Lithium induces tau-mediated iron accumulation in neuronal culture

Having found that by inducing nigral tau suppression lithium treatment of normal mice recapitulated a series of abnormalities that appear in tau-knockout mice (nigral iron elevation with dopaminergic neurodegeneration and parkinsonism), we investigated the mechanism in mouse primary cortical neuronal cultures. Lithium (at nontoxic concentrations) induced significant iron accumulation within 18 h in a dose-dependent manner (5 mM Li: +48%, P = 0.005; 10 mM Li: +56%, P < 0.001; Figure 3a), but did not alter copper or zinc levels (Figure 3b), consistent with the changes in brain levels of these metals in mice treated with lithium (Figure 2c). Lithium (10 mM) significantly inhibited the efflux of iron (chased after 59Fe loading) into the media (P < 0.001; Figure 3c), explaining the retention of iron. As expected, lithium treatment (10 mM) had no effect on zinc retention in primary neurons treated with radio-labeled 65Zn (P = 0.176, Supplementary Figure 8).
The activities of both IMPase and GSK-3 (ref. 5) are considered molecular targets for lithium's therapeutic effect in bipolar disorder.\textsuperscript{3} L-690,330, a potent and more specific inhibitor of IMPase,\textsuperscript{76} had no effect on cellular iron level during the 18-h incubation ($P = 0.106$; Supplementary Figure 9a), thus eliminating IMPase in the mechanism of iron accumulation induced by lithium. However, BIO, a potent and specific inhibitor of GSK-3,\textsuperscript{77} caused iron retention similar to the effect of lithium ($P = 0.059$; Supplementary Figure 9b).

Both lithium and BIO are reported to decrease total tau protein levels in addition to their inhibitory effects of GSK in cultured neurons.\textsuperscript{42} In agreement with previous reports,\textsuperscript{31,42} we found that lithium ($\geq 5\, \text{mM}, 18$ h) suppresses tau protein levels in primary neurons ($5\, \text{mM}$ Li: $-48\%$, $P = 0.007$; $10\, \text{mM}$ Li: $-35\%$, $P = 0.034$; Figure 3d) and in SH-SY5Y cells ($5\, \text{mM}$ Li: $-25\%$, $P = 0.003$; $10\, \text{mM}$ Li: $-25\%$, $P = 0.002$; Supplementary Figures 10a and b). BIO (18 h) also suppressed tau protein levels in primary neuronal culture ($1\, \mu\text{M}$ BIO: $-25\%$, $P = 0.043$; $2\, \mu\text{M}$ BIO: $-26\%$, $P = 0.048$; Supplementary Figures 10c and d) that may be the mechanism for its ability to increase neuronal iron levels.

To demonstrate the requirement for tau in the mechanism of lithium-induced iron accumulation in neurons, lithium ($10\, \text{mM}, 18$ h) was administered to tau-knockout primary neurons and compared with background-matched wild-type neurons (Figure 3e). As previously shown,\textsuperscript{33} tau-knockout neurons retained more iron ($+20\%$, $P = 0.032$) compared with wild-type neurons. As expected, lithium treatment ($10\, \text{mM}, 18$ h) of wild-type neurons induced a significant accumulation of iron ($+20\%$, $P = 0.038$), but lithium treatment of tau-knockout neurons induced no further iron accumulation. Thus, lithium-enhanced neuronal iron accumulation requires the expression of tau protein.

Tau-knockout and APP-knockout mice are resistant to neurodegeneration caused by chronic lithium administration Tau mediates neuronal iron efflux by facilitating the trafficking of APP to the cell surface, where it stabilizes the iron export channel ferroportin.\textsuperscript{43,52} To test whether lithium-induced iron accumulation requires APP, we applied the same lithium treatment to tau-knockout mice, APP-knockout mice and their background-matched wild-type mice. We studied mice at 3 months of age, because the knockouts have yet to develop the age-dependent elevation in brain iron levels.\textsuperscript{43,44}

All three strains showed no weight reduction during 21 days of lithium treatment (Figure 4a), even though APP knockouts were lighter in weight (as reported previously\textsuperscript{78}). Lithium treatment predictably caused an elevation in mouse plasma lithium levels (wild type: $+6.6$-fold, $P = 0.001$; tau knockout: $+6.7$-fold, $P = 0.001$; APP knockout: $+4.3$-fold, $P = 0.007$; Figure 4b), although the levels in all three strains remained well below the lower limit of the therapeutic concentration range.\textsuperscript{40} As with the B6/C57J mice (Figure 2c), lithium treatment induced iron elevation in both the cortex and SN of the littermate B6/C57J5v mice (cortex: $+15\%$, $P = 0.031$; SN: $+20\%$, $P = 0.041$), but despite lithium elevations in brain regions being commensurate to those in B6/C57J mice (Figure 2b), tau- and APP-knockout mice were unaffected (Figure 4c) and consistent with the neuronal culture findings (Figure 3e). Brain copper or zinc levels were again unaffected (Supplementary Figures 11a–d), and iron levels in the cerebellum and liver were unaltered (Supplementary Figures 11e and f), by lithium treatment in all three strains.

Ablation of APP abolished lithium-induced iron accumulation (Figures 4c and d), despite soluble tau protein levels in cortex and SN of APP-knockout mice treated with lithium being suppressed comparably to wild type (cortex: $-19\%$, $P = 0.004$ for wild type and $-41\%$, $P = 0.006$ for APP knockout; SN: $-42\%$, $P = 0.001$ for wild type and $21\%$, $P = 0.041$ for APP knockout; Figures 4e and f and Supplementary Figure 12). These results confirm our prediction that lithium-induced brain iron accumulation requires both tau and APP expression, with tau being upstream in the APP-associated iron homeostatic pathway.

As lithium-induced Parkinson-like symptoms such as hand tremor may be mediated by iron accumulation in the brain, disabling lithium-induced SN iron accumulation in tau- and APP-knockout mice (Figure 4d) should also prevent motor deficits and SN neuronal loss. Indeed, lithium-induced motor deficits were abolished in tau- and APP-knockout mice, as evidenced by unaffected time to turn (wild type, $P = 0.020$; Figure 4g) and time to finish (wild type, $P = 0.048$; Supplementary Figure 13a) in the Pole test, and unaltered average distance per movement (wild type, $P = 0.049$; Figure 4h), distance of locomotion (wild type, $P = 0.020$; Supplementary Figure 13b) and velocity (wild type, $P = 0.048$; Supplementary Figure 13c) in the open field test. Untreated APP-knockout mice did show baseline motor deficits (Figures 4g and h and Supplementary Figures 13a–c), as previously reported,\textsuperscript{78} but these were not worsened by lithium. Tau or APP ablation also negated SN dopaminergic neuron loss induced by lithium treatment (wild type, $P < 0.001$; Figure 4i and Supplementary Figure 14a). Together, these results support the conclusion that lithium-induced parkinsonism is mediated by iron accumulation that is tau and APP dependent.

As lithium treatment also increases cortical iron levels (Figures 2c and 4c), we investigated its effect on cognitive performance and related brain anatomy. In the Y-maze test, we found the memory performance of wild-type mice was markedly impaired by 21 days of lithium treatment ($P = 0.022$) but, as with the Pole test (Figure 4g), tau- and APP-knockout mice were unaffected by lithium (Figure 4i). Accordingly, lithium treatment caused brain atrophy in wild-type mice, evidenced by enlarged lateral ventricular area ($+72\%$, $P = 0.023$; Figures 4k and l), shrinkage of CPu area ($-13\%$, $P = 0.011$; Supplementary Figure 14b) and reduced cortical thickness ($-7\%$, $P = 0.040$; Supplementary Figure 14c), without affecting corpus callosum width (Supplementary Figure 14d). Again, lithium did not induce brain atrophy in tau- or APP-knockout mice (Figure 4l and Supplementary Figures 14c and d). These toxic consequences of lithium administration to cortical thickness are in agreement with a previous report that found cortical neuronal apoptosis in mice upon chronic lithium treatment.\textsuperscript{78}

**DISCUSSION**

Lithium has an established record of efficacy in bipolar affective disorder, despite a narrow therapeutic window limited by various toxicities of uncertain mechanism. Here we found that lithium may contribute to nigral and cortical degeneration, with motor and cognitive impairment in wild-type mice, recapitulating the neurophysiological and neurochemical phenotypes of aged tau-knockout mice.\textsuperscript{43,44} Lithium suppresses tau protein levels in cultured neurons and in mice, causing iron accumulation through a tau- and APP-dependent interaction. The $T_2$ relaxation time changes in the human lithium trial are consistent with iron elevation in hippocampus and SN. Although homeostasis keeps brain iron levels stringently stable in health, and geared to resist depletion,\textsuperscript{79} rodent studies have shown that nearly 10% of brain iron is in relatively rapid exchange with dietary iron\textsuperscript{80} indicating that in order to prevent iron accumulation, iron efflux from the brain must be constantly active. It is this mechanism that lithium inhibits by, at least in part, suppressing tau expression. Tau-knockout mice develop iron-induced neurodegenerative changes at 12 months of age\textsuperscript{43,44} but lithium-induced toxic iron accumulation occurs within weeks. This is probably because the tau-knockout mice in youth have the benefit of upregulated compensatory responses from other microtubule-associated proteins\textsuperscript{45} in contrast to the more acute suppression of tau expression by lithium treatment. Our findings add to the evidence...
that lithium at therapeutic (and eventually even at subtherapeutic) chronic doses can cause neurodegeneration,17 and provide a possible mechanism for adverse neurological effects in susceptible individuals.

Parkinsonism is an uncommon adverse effect of lithium treatment, but hand tremor is common and may be age and dose dependent.81–83 In addition, lithium use was found to be associated with an increased incidence of anti-parkinson drug use or a PD diagnosis.16 The mechanisms underlying these motor abnormalities are not known, but could be because of persistent or transient extrapyramidal syndromes caused by damage to the basal ganglia and SN. Iron may play a critical role in promoting SN pathology in PD,55,84 and our findings demonstrate how lithium could worsen iron-mediated SN damage. SN iron accumulation in trial subjects may have occurred after only 3 months of low-dose lithium treatment (Figure 4b), although no conspicuous motor abnormalities were reported in this group. In addition, our findings in mice support the possibility that lithium-induced parkinsonism can become irreversible in a proportion of patients.6,8,11,15

Unexpectedly, we found that lithium treatment at doses inducing blood levels well below the human therapeutic range caused cognitive impairment and brain atrophy in mice after 3 weeks (Figures 4j–l). It has been shown previously that lithium treatment at therapeutic doses can cause cortical neuronal apoptosis,17 and this may explain our findings. Although lithium treatment was previously reported to correct the smaller hippocampal volumes in patients with bipolar disorder,85 there is also evidence that long-term lithium treatment is associated with cognitive impairment66–68 and brain atrophy.89 Neurodegeneration in mice administered lithium to achieve blood levels that are easily tolerated by humans may reflect different pharmacodynamics in the species, or that humans are less sensitive than mice to lithium-induced neurotoxicity.

Lithium-induced motor deficits in mice are reported to involve the calcineurin/nuclear factor of activated T cells (NFAT)/Fas ligand signaling pathway, and prevented by inhibition of calcineurin or knockout of Fas.17 Iron modulates calcineurin activity90,91 and can thereby impact the NFAT/Fas signaling pathway. Treatment with iron dramatically elevates NFAT activity,92,93 whereas administering the iron chelator deferoxamine abolishes iron-induced NFAT activation.92,93 Together with our current data, a proposed model pathway emerges (Figure 5) where lithium suppresses tau protein levels, thus preventing APP trafficking to the cell surface and resulting in neuronal iron retention. In turn, this activates calcineurin/NFAT/Fas signaling induces cortical and nigral neuronal apoptosis and engenders motor and cognitive disability.

Lithium was an attractive drug candidate for AD as its target, GSK-3, regulates both Aβ production and tau phosphorylation.9 However, it is neither a potent nor specific inhibitor of GSK-3.94 In fact, neuronal deficits have been reported to result from both genetic reduction and specific inhibition of GSK-3.95,96 highlighting the risk of inhibiting this enzyme.97 Lithium arrests neuropathology in some AD rodent models,36,38,39 but these are aggressive models driven by transgene overexpression, where the benefits of lithium inhibiting a dominant pathological target (for example, tau hyperphosphorylation) outweigh lithium-induced neurotoxicity. The lithium-induced neurotoxicity that we and others17,39 observed might only be detected in normal mice or mice that do not express a neuropathology that is inhibited by lithium.

Our current study might help explain the failure of trials of lithium for AD90,96 and amyotrophic lateral sclerosis,99–101 both diseases where elevated iron in the affected tissue has been implicated in pathogenesis.52,102–104,105 Despite the neurotoxicity in mice that our studies have elaborated, clinical lithium pharmacotherapy has predominantly neurotrophic benefits in the treatment of bipolar disorder. It is an intriguing hypothesis to consider that these benefits might be related to the correction of iron deficiency in certain brain regions.

CONFLICT OF INTEREST
Dr Finkelstein is a paid scientific consultant for Prana Biotechnology. Dr Bush is a shareholder in Prana Biotechnology, Eucalyptus, Mesoblast, Brighton Biotech and Nextvet, and a paid consultant for Collaborative Medicinal Developments. Dr Pantelis has participated on Advisory Boards for Janssen-Cilag, Astra-Zeneca, Lundbeck and Servier. He has received honoraria for talks presented at educational meetings organized by Astra-Zeneca, Janssen-Cilag, Eli Lilly, Pfizer, Lundbeck and Shire. Dr McGorry receives unrestricted research funding from Astra-Zenica, Eli Lilly, Janssen-Cilag, Pfizer and Novartis, as well as honoraria for educational activities with Astra-Zenica, Eli Lilly, Janssen-Cilag, Pfizer, Bristol Myer Squibb, Roche and the Lunbeck Institute. The remaining authors declare no conflicts of interest.

ACKNOWLEDGMENTS
We thank A Sedjahtera, L Lam, L Gunawan, L Bray and K Wikhe for technical assistance. We also acknowledge L Phillips and B Nelson for their contributions in lithium human trial. This study was supported by funds from the Australian Research Council, the National Health & Medical Research Council (NHMRC) of Australia, the Cooperative Research Center for Mental Health, Alzheimer’s Australia Dementia Research Foundation and National Natural Science Foundation of China (81571236). A Bush was supported by a NHMRC Australia Fellowship (AF79) and a NHMRC Senior Principal Research Fellowship (1103703). C Pantelis was supported by a NHMRC Senior Principal Research Fellowship (628386 and 1105825). The imaging work on lithium was supported by NHMRC Project Grant (145627) and NHMRC Program Grants (350241 and S66529). P McGorry currently receives research support from NHMRC of Australia, the Colonial Foundation and NARSAD. Florey Institute of Neuroscience and Mental Health acknowledges the strong support from the Victorian Government and in particular the funding from the Operational Infrastructure Support Grant.

AUTHOR CONTRIBUTIONS
PL and AIB conceived and raised funds for the study. PL, SA, JAD, RC, DIF and AIB designed and performed the experiments. ATA, SM, IV and MG and assisted with the experiments. SJW, GB, CP, PM and AY conducted the lithium human trial. PL and AIB integrated the data and wrote the drafts of the manuscript. All authors edited the manuscript.

Figure 5. A model of affected pathways for lithium-induced neurodegeneration. Lithium (Li) treatment suppresses soluble tau protein levels that prevent APP trafficking to the neuronal surface. Lack of surface amyloid protein precursor (APP) destabilizes ferroportin (Fpn), resulting in iron accumulation. Elevated iron activates calcineurin/nuclear factor of activated T cells (NFAT)/Fas signaling that then induces neuronal apoptosis, engendering motor and cognitive disability.
Author/s:
Lei, P; Ayton, S; Appukuttan, AT; Moon, S; Duce, JA; Volitakis, I; Cherny, R; Wood, SJ; Greenough, M; Berger, G; Pantelis, C; McGorry, P; Yung, A; Finkelstein, DI; Bush, AI

Title:
Lithium suppression of tau induces brain iron accumulation and neurodegeneration

Date:
2017-03-01

Citation:
Lei, P; Ayton, S; Appukuttan, AT; Moon, S; Duce, JA; Volitakis, I; Cherny, R; Wood, SJ; Greenough, M; Berger, G; Pantelis, C; McGorry, P; Yung, A; Finkelstein, DI; Bush, AI, Lithium suppression of tau induces brain iron accumulation and neurodegeneration, MOLECULAR PSYCHIATRY, 2017, 22 (3), pp. 396 - 406

Persistent Link:
http://hdl.handle.net/11343/112362

File Description:
Accepted version